PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer

2013-11-06
(Press-News.org) Contact information: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer
Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer Long term results of the randomized phase III EORTC intergroup trial 40983 were recently reported in The Lancet Oncology. The observed 4.1% difference in overall survival at five years for patients with initially resectable liver metastases from colorectal cancer was not significant for perioperative chemotherapy with FOLFOX4 (folinic acid, fluorouracil, and oxaliplatin) compared with surgery alone. Earlier results of this same trial had shown that perioperative chemotherapy with FOLFOX4 increases progression-free survival (the primary endpoint) compared with surgery alone for these patients. Overall survival was a secondary endpoint, and the trial was not initially powered to compare overall survival in the two groups. Consequently, the authors conclude that perioperative chemotherapy with FOLFOX4 should remain the reference treatment for this population of patients.

Prof. Bernard Nordlinger of the Centre Hospitalier Universitaire Ambroise Paré, Assistance Publique–Hôpitaux de Paris, Université de Versailles, Boulogne- Billancourt, France, and member of the EORTC Gastrointestinal Tract Cancer Group says, "Surgery is currently the only potentially curative treatment for resectable liver metastases, yet only 15–20% of patients with hepatic metastases are initially eligible for a radical surgical treatment. Furthermore, less than one half of patients who do receive such treatment achieve 5-year survival after resection. This is likely due to the presence of residual disease, so it is thought that adjuvant chemotherapy could help these patients."

EORTC intergroup trial 40983 recruited 364 patients between the ages of 18-80 years with colorectal cancer and up to four liver metastases. Patients were randomly assigned to either perioperative FOLFOX4, 182 patients, or surgery alone, 182 patients. Of these, eleven patients per group were deemed to be ineligible.

At a median follow-up of 8.5 years (Interquartile range 7•6 years–9•5 years), 59% of all randomized patients in the perioperative chemotherapy group had died as opposed to 63% in the surgery alone group (Hazard ratio 0.88, 95% confidence interval (CI) 0•68–1•14; p=0•34). Median overall survival was 61.3 months (95% CI 51.0–83.4) for patients receiving perioperative chemotherapy and 54.3 months (95% CI 41.9–79.4) for those receiving surgery alone, while the 5-year overall survival was 51.2% (95% CI 43.6–58.3) in the perioperative chemotherapy group and 47.8% (95% CI 40.3–55.0) in the surgery-only group. In eligible patients (171 per group), estimated 5-year overall survival was 52.4% in the perioperative chemotherapy group versus 48.3% in the surgery alone group.

Five patients (two patients in the perioperative chemotherapy group and three in the surgery-only group) passed away due to complications from surgery. One additional death in the perioperative chemotherapy group was possibly a result of toxicity from the protocol treatment.

### EORTC trial 40983 was coordinated by the EORTC Gastrointestinal Tract Cancer Group in collaboration with Australasian Gastro-Intestinal Trials Group, Arbeitsgruppe Lebermetastasen und -tumoren in der Chirurgischen, Arbeitsgemeinschaft Onkologie, Cancer Research Campaign Clinical Trials Unit – UK, and Fédération Francophone de Cancérologie Digestive. It was conducted at 78 hospitals located in eleven countries: Australia, Austria, Belgium, France, Germany, Hong Kong, Italy, Norway, Sweden, The Netherlands, and the United Kingdom.

This trial was supported by an educational grant from Sanofi -Aventis, by grants from the Norwegian and Swedish Cancer Societies, Cancer Research UK, and the Ligue Nationale Contre le Cancer (France) through the EORTC Charitable Trust, and the United States of America National Cancer Institute grants 5U10-CA11488-28 to 5U10 CA11488-40.


ELSE PRESS RELEASES FROM THIS DATE:

For young baseball players, light bats don't hit too fast

2013-11-06
For young baseball players, light bats don't hit too fast PROVIDENCE, R.I. [Brown University] — With some fierce pitching on display, this year's World Series featured its share of shattered wood bats. That's a problem many youth baseball players avoid by using ...

'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's

2013-11-06
'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs ...

Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study

2013-11-06
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study Results of an EORTC study published in Cancer point out the prognostic value of baseline recorded health-related quality of life for survival for ...

Nature's great diversity: Remarkable 277 new wasp species from Costa Rica

2013-11-06
Nature's great diversity: Remarkable 277 new wasp species from Costa Rica Costa Rica reveals astonishing biodiversity of braconid wasps, with 277 new species of the tribe Heterospilini described in the latest special issue of the open access journal ZooKeys. This is the second ...

Touch may alleviate existential fears for people with low self-esteem

2013-11-06
Touch may alleviate existential fears for people with low self-esteem As human beings, we all know that we are going to die some day. Most of us deal with this knowledge by trying to live meaningful lives, but people with low self-esteem ...

NIST's new compact atomic clock design uses cold atoms to boost precision

2013-11-06
NIST's new compact atomic clock design uses cold atoms to boost precision Physicists at the National Institute of Standards and Technology (NIST) have demonstrated a compact atomic clock design that relies on cold rubidium atoms instead ...

Cocktail novelties inspired by nature's designs

2013-11-06
Cocktail novelties inspired by nature's designs Mechanisms behind water bugs and lilies applied to culinary devices CAMBRIDGE, MA -- An MIT mathematician and a celebrity chef have combined talents to create two culinary novelties inspired by nature. John ...

Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications

2013-11-06
Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications Researchers from the National Institute of Standards and Technology (NIST) have joined with an international team to engineer and ...

Recent National Science Foundation study reveals increase in state government expenditures for research and development

2013-11-06
Recent National Science Foundation study reveals increase in state government expenditures for research and development According to a recent study published by the National Science Foundation (NSF), state government agency expenditures for research and development ...

Updating building energy codes: How much can your state save?

2013-11-06
Updating building energy codes: How much can your state save? How much in energy and cost savings would your state realize if it updated its commercial building energy codes? You can find out in a new on-line publication* from the National ...

LAST 30 PRESS RELEASES:

Global South cities hold key to unlocking healthcare solutions – studies show

Autism not linked with increased age-related cognitive decline

Study shows 90% metal pollution drop in Adirondack waters five decades after the clean air act

Can technology revolutionize health science? The promise of exposomics

Human pressure most affecting Atlantic Rainforest deer density, study finds

The effects of smoking, drinking and lack of exercise are felt by the age of 36, new research indicates

Nanophotonic platform boosts efficiency of nonlinear-optical quantum teleportation

Scientists urge plastic limit for lateral flow tests

Prepare today to save lives tomorrow: SFU study finds gaps in B.C. extreme heat response plans

National Foundation for Cancer Research congratulates Dr. Rakesh Jain on AACR Lifetime Achievement Award

Farms with more intensive management have lower soil functionality

Tracing the emergence and spread of H5N1 in U.S dairy cattle

Carnivorous “bone collector” caterpillar patrols spiderwebs while adorned in body parts of its insect prey

New approach to silicone waste recycling closes the loop

Blocking a surprising master regulator of immunity eradicates liver tumors in mice

A new recycling process for silicones could greatly reduce the sector’s environmental impacts

Simple consultations in emergency room can help patients manage high blood pressure

Metachromatic Leukodystrophy (MLD) and gene therapy: a game-changing treatment backed by NEJM—Timing Is Everything

Estimating complex immune cell structures by AI tools for survival prediction in advanced melanoma

Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US

2024 Top 100 US Universities announced by the National Academy of Inventors

Female bonobos keep males in check—not with strength, but with solidarity

What happens in the brain when your mind blanks

The oldest ant ever discovered found fossilized in Brazil

Health care cost concerns and hardships for families of children with disabilities

Trends in mental health diagnoses among publicly insured children

Measles may be making a comeback in the US, Stanford Medicine-led research finds

We still have a representation problem for women in physics – and Canada is no exception

Even light exercise could help slow cognitive decline in people at risk of Alzheimer’s

Prostate cancer discovery opens door to more tailored treatments

[Press-News.org] Long term results of EORTC trial for patients with resectable liver metastases from colorectal cancer